Search research articles
Contact Us
Filters
Showing results (61-70 of 99) with videos related to
Page
of 10
Sort By:
Transplantation and Cellular Therapy
|
May 19, 2024
TACTUM: Trends in Access to Cellular Therapies in Multiple Myeloma, Perspectives of Treating Versus Referring Physicians
Rawan Atallah, Nausheen Ahmed, Fathima Ayoobkhan, et al.
Blood Cancer Journal
|
May 31, 2024
Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy
Danai Dima, Al-Ola Abdallah, James A Davis, et al.
Transplantation and Cellular Therapy
|
December 27, 2023
Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience
Danai Dima, James A Davis, Nausheen Ahmed, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
October 26, 2025
Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial
Ishita Kamboj, Alma Habib, Darryl Chang, et al.
Transplantation and Cellular Therapy
|
March 30, 2021
Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell Lymphoma
Abu-Sayeef Mirza, Ambuj Kumar, Hamza Hashmi, et al.
Transplantation and Cellular Therapy
|
June 13, 2024
Timing of Toxicities and Non-Relapse Mortality Following CAR T Therapy in Myeloma
William Wesson, Danai Dima, Nahid Suleman, et al.
Blood Advances
|
October 21, 2021
Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis
Mehdi Hamadani, Ajay K Gopal, Marcelo Pasquini, et al.
Transplantation and Cellular Therapy
|
November 14, 2021
Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial Outcomes
Paul V O'Donnell, Claudio G Brunstein, Ephraim J Fuchs, et al.
Blood Cancer Journal
|
April 12, 2026
Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma
Hamza Hashmi, Tara Sebastian, Sridevi Rajeeve, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 26, 2026
Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific Antibodies
Issam S Hamadeh, Maximillian Merz, Andriy Derkach, et al.
Page
of 10
Search research articles
Search
Showing results (61-70 of 99) with videos related to
Sort By:
Page
of 10
Transplantation and Cellular Therapy
|
May 19, 2024
TACTUM: Trends in Access to Cellular Therapies in Multiple Myeloma, Perspectives of Treating Versus Referring Physicians
Rawan Atallah, Nausheen Ahmed, Fathima Ayoobkhan, et al.
Blood Cancer Journal
|
May 31, 2024
Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy
Danai Dima, Al-Ola Abdallah, James A Davis, et al.
Transplantation and Cellular Therapy
|
December 27, 2023
Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience
Danai Dima, James A Davis, Nausheen Ahmed, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
October 26, 2025
Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial
Ishita Kamboj, Alma Habib, Darryl Chang, et al.
Transplantation and Cellular Therapy
|
March 30, 2021
Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell Lymphoma
Abu-Sayeef Mirza, Ambuj Kumar, Hamza Hashmi, et al.
Transplantation and Cellular Therapy
|
June 13, 2024
Timing of Toxicities and Non-Relapse Mortality Following CAR T Therapy in Myeloma
William Wesson, Danai Dima, Nahid Suleman, et al.
Blood Advances
|
October 21, 2021
Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis
Mehdi Hamadani, Ajay K Gopal, Marcelo Pasquini, et al.
Transplantation and Cellular Therapy
|
November 14, 2021
Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial Outcomes
Paul V O'Donnell, Claudio G Brunstein, Ephraim J Fuchs, et al.
Blood Cancer Journal
|
April 12, 2026
Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma
Hamza Hashmi, Tara Sebastian, Sridevi Rajeeve, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 26, 2026
Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific Antibodies
Issam S Hamadeh, Maximillian Merz, Andriy Derkach, et al.
Page
of 10